International: +1-347-960-6455
Plague Therapeutics - Pipeline Analysis 2018

Plague Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10069 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Infectious
Select License Type

Plague is an enzootic vector borne disease and a type of infectious disease, that is caused by the bacterium Yersinia pestis. This bacterium is generally found in the flea that affects human and other mammals. This disease is categorized by the concentrated areas of the infection, such as septicemic, pneumonic, and bubonic plague. Septicemic plague is related to blood, bubonic plague is related to the lymph nodes, and pneumonic plague is related to lungs. However, the direct transmission of the pathogens is also observed in the case of pneumonic plague. Prokarium Ltd. is in the process of developing a vaccine for plague. Aradigm Corporation is also in the process of developing ARD-1100 as a DNA topoisomerase IV inhibitor for the treatment of plague.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.